Home LiteratureArticle Details
PMID: 9041466 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons.

Subramaniam PS, Johnson HM

Abstract

Type I interferons (IFN), such as IFN-alpha, are potent antiproliferative and antitumor agents. IFN-tau, originally identified as a pregnancy recognition hormone, is a type I IFN that is related to IFN-alpha. We examine here the mechanism of the antiproliferative effects of IFN-alpha and IFN-tau in terms of their effects on intracellular events that regulate the cell cycle. Both IFN inhibited proliferation of the human Burkitt lymphoma cell line, Daudi, causing accumulation of cells in the G1 phase of the cell cycle. IFN-alpha was more effective than IFN-tau in this regard. Both IFN were found to inhibit the kinase activity of the cyclin-dependent kinase cdk2 in a manner that correlated with their relative abilities to cause cells to accumulate in the G1 phase of the cell cycle. Further, IFN treatment did not affect the expression of cdk2 protein, suggesting that the IFN modulated cdk2 activity through a cdk inhibitor. Consistent with this conclusion, both IFN induced the expression of the cyclin-dependent kinase inhibitor protein p21. The levels of p21 induced also correlated with the relative abilities of the IFN to inhibit cdk2 activity and to arrest cell growth in the G1 phase of the cell cycle. Moreover, following IFN treatment, increased levels of p21 were found complexed with cdk2, consistent with its role in the inhibition of cdk2 activity. These data suggest that p21-mediated inhibition of cdk2 activity plays an important role in the antiproliferative activity of type I IFN. The findings highlight interesting similarities between these cytokines and the products of tumor suppressor genes, such as p53, and may indicate a mechanism for the antitumor effects of the type I IFN.

MeSH Terms
Antineoplastic Agents/pharmacology Burkitt Lymphoma/drug therapy,pathology CDC2 Protein Kinase/antagonists & inhibitors Cell Division/drug effects Cyclin-Dependent Kinase Inhibitor p21 Cyclin-Dependent Kinases/antagonists & inhibitors Cyclins/physiology Enzyme Inhibitors/metabolism G1 Phase/drug effects Humans Interferon Type I Interferon-alpha/pharmacology Interferon-gamma/pharmacology Pregnancy Proteins/pharmacology Tumor Cells, Cultured
Chemicals
Antineoplastic Agents CDKN1A protein, human Cyclin-Dependent Kinase Inhibitor p21 Cyclins Enzyme Inhibitors Interferon Type I Interferon-alpha Pregnancy Proteins interferon tau Interferon-gamma CDC2 Protein Kinase Cyclin-Dependent Kinases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Subramaniam P S
Department of Microbiology and Cell Science, University of Florida, Gainesville 32611, USA.
Johnson H M
Article Info
Journal
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
Abbr.
J Interferon Cytokine Res
ISSN
1079-9907
Published
1997-01-00
Pages
11-5
Language
English
Region
United States
NLM ID
9507088
Subset
IM
Grants
NCI NIH HHS · CA 69959 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com